You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants

    SBC: 149 MEDICAL INC            Topic: 103

    PROJECT SUMMARY/ABSTRACT Every year in the United States about 30% of the 60,000 infants born extremely premature (andlt;30 weeks gestational age and andlt;1000 g birth-weight [ELGA]) develop intraventricular hemorrhage (IVH). IVH is associated with high risk for cerebral palsy and significant intellectual disability, causing lifelong implications for affected children and their families and consi ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Thermostable Inactivated Potent Yellow Fever Vaccine

    SBC: UNIVERSAL STABILIZATION TECHNOLOGIES, INC.            Topic: NIAID

    SummaryYellow Fever (YF) is an acute viral hemorrhagic fever disease caused by Yellow Fevervirus (YFV) and an estimated 200,000 YF infections occur annually. Approximately 50% ofinfected individuals that develop a severe case of the disease will die. The infection iscommon in Africa and South America, and travelers and residents of those areas are athigh risk of contracting the virus. A recent res ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Spray-based visual indicator of opioids for the rapid and effective decontamination of large areas

    SBC: TRITON SYSTEMS, INC.            Topic: CBD20AT001

    Triton Systems, Inc. will collaborate with The University of Massachusetts Lowell to develop a spray-based technology for the rapid, visual identification of opioids, turning contaminated areas from nondescript white powders to a brightly colored spots for easy recognition with the naked eye. The technology leverages molecular recognition units that bind strongly and specifically to a variety of o ...

    STTR Phase I 2021 Department of DefenseOffice for Chemical and Biological Defense
  4. Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

    SBC: FILTRO MEDICAL INC.            Topic: NCI

    PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Fingerprinting Cancer via Multiparameter Extracellular Vesicle Analysis

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 102

    Project Summary Electronic BioSciences (EBS) proposes, in collaboration with Distinguished Professor Henry White at the University of Utah, to develop a nanopore-based extracellular vesicle (EV) characterization system capable of high-resolution, single-vesicle, solution-based characterization, sorting, and isolation. EVs are nanometer-scale, cell-derived vesicles that are produced by nearly all m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Cancer Immunotherapy Targeting Tn Antigen

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 100

    AbstractCancer immunotherapeutic bi-specific proteins and engineered Chimeric Antigen Receptor T cells (CAR T) have shown remarkable clinical activity, with complete response rates as high as ~90% for B cell malignancies. However, applying these two therapeutic approaches to the vast majority of cancer types is restricted by multiple factors. First, there are only a small number of known cell-surf ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Bronchoscopic lung navigation system for accurately excising lung nodules

    SBC: Navigation Sciences, Inc.            Topic: 102

    ABSTRACT The long-term goal of this project is to develop and commercialize a navigation system that can accurately determine margins in real-time during surgery for lung cancer. Surgery is currently the standard of care for early stage lung cancer. A critical challenge is to reliably identify small, early-stage tumors and resect them with sufficient margins (distance between the edge of tumor and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa

    SBC: COURAGE THERAPEUTICS INC            Topic: 101

    Anorexia nervosa (AN) is a devastating neuropsychiatric disease with a high prevalence (up to 2.2% of women) and significant morbidity and mortality. There are currently no effective therapeutic agents for the disorder. The goal of Courage Therapeutics is the development of melanocortin-3 receptor (MC3R) -specific agonist peptides for the treatment of anorexia nervosa. The product of this Phase I ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease

    SBC: Circumvent Pharmaceuticals            Topic: NICHD

    SummaryIn the Specific Aims outlined by the following proposal for an NIH SBIR Phase 1 project, we will use a multi-faceted approach to identify key substrates for targeted assay development to monitor therapy in for CLN1 Batten Disease (CLN1). CLN1 is an ultra-rare neurodegenerative disease that affects children with autosomal recessive mutations in the gene for palmitoyl-protein thioesterase 1 ( ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government